national stem-cell therapy logo

RoslinCT Unveils CRISPR: A Medical Revolution Begins

roslinCT logo

RoslinCT, a renowned cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has announced a significant advancement in the field of medical science. They will be manufacturing the world’s first CRISPR-based therapy, exa-cel, for Vertex Pharmaceuticals Inc. This development follows an extensive collaboration between the two entities. Key Highlights: About RoslinCT: RoslinCT has a […]

Be The Match BioTherapies and Cryoport Join Forces to Propel Cell and Gene Therapy Advancements

Be The Match Logo

In a groundbreaking move, Be The Match BioTherapies®, a pioneering organization that offers solutions for companies venturing into the development and commercialization of cell and gene therapies, has announced a strategic partnership with Cryoport, a global leader in providing innovative products and services to the rapidly evolving cell & gene therapy sector. A Partnership for […]

Orchard Therapeutics Moves Closer to a Breakthrough Treatment for MLD

Orchard Therapeutics

Orchard Therapeutics, a global leader in gene therapy, has recently made significant strides in the development of a treatment for metachromatic leukodystrophy (MLD). Here’s a detailed summary of the press release: Key Developments: Insights from Orchard Therapeutics: Bobby Gaspar, M.D., Ph.D., co-founder and CEO of Orchard Therapeutics, expressed the company’s commitment to addressing the urgent […]

Excision BioTherapeutics’ Groundbreaking Gene Therapy for HIV: A Closer Look

excision-logo-wordmark-blue-green

Excision BioTherapeutics, a clinical-stage biotechnology company, has recently made headlines with its announcement regarding the publication of pre-clinical data supporting its innovative CRISPR-based gene therapy candidate, EBT-101. This therapy is designed to functionally cure HIV-1. Here’s a detailed summary of the press release: Key Findings: CEO’s Statement: Daniel Dornbusch, the Chief Executive Officer of Excision, […]

RoslinCT and Lykan Bioscience: The Dynamic Duo Redefining the Future of Cell and Gene Therapy

RoslinCT and Lykan Bioscience

RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, have announced their integration to form a unified business that will operate under the RoslinCT brand. This integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell […]

Cell and Gene Therapy Companies Leverage GenScript’s cGMP sgRNA Capability to Accelerate Speed to Market

PISCATAWAY, N.J., Dec. 15, 2022 /PRNewswire/ — GenScript USA Inc., the world’s leading life-science service provider, recently expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies. GenScript’s 400,000 square-foot cGMP facility enables next-generation gene and cell therapy R&D programs to advance IND filings and clinical trials. “We are […]

Researchers Say They Are Close To Reversing Aging

NBC News - researchers are close to reversing aging

Researchers at Harvard University are investigating whether human genes could reverse the effects of aging. NBC Medical Fellow Dr. Akshay Syal got exclusive access to Dr. David Sinclair and his lab to discuss the future of how to defy aging.

BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH

TreeFrog's C-Stem technology

BORDEAUX, France, Oct. 11, 2022 /PRNewswire/ — TreeFrog Therapeutics, a biotechnology company developing stem cell-derived therapies in regenerative medicine and immuno-oncology based on the biomimetic C-Stem™ technology platform, and Invetech, a global leader in the development and production of automated manufacturing solutions for cell and advanced therapies, today announced the delivery of a GMP-grade cell encapsulation device using the C-Stem™ technology. […]

Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas

Orchard Therapeutics

BOSTON and LONDON, Oct. 10, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced multiple presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh. Clinical and pre-clinical data from across the company’s hematopoietic stem cell […]